SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-014670
Filing Date
2017-08-01
Accepted
2017-08-01 16:53:19
Documents
46
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-10q_20170630.htm 10-Q 1294442
2 EX-31.1 ntla-ex311_9.htm EX-31.1 8311
3 EX-31.2 ntla-ex312_10.htm EX-31.2 8271
4 EX-32.1 ntla-ex321_8.htm EX-32.1 6019
5 GRAPHIC g20170801204013222159.jpg GRAPHIC 53205
  Complete submission text file 0001564590-17-014670.txt   3754867

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ntla-20170630.xml EX-101.INS 668384
7 XBRL TAXONOMY EXTENSION SCHEMA ntla-20170630.xsd EX-101.SCH 28769
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20170630_cal.xml EX-101.CAL 25243
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20170630_def.xml EX-101.DEF 61114
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20170630_lab.xml EX-101.LAB 220799
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20170630_pre.xml EX-101.PRE 155660
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 17997334
SIC: 2835 In Vitro & In Vivo Diagnostic Substances